NICE Rejects Expanded Use for AstraZeneca’s Lynparza

NICE denied expanded approval for the pill form of AstraZeneca’s Lynparza (olaparib), an oncology targeted therapy approved for recurrent ovarian cancer and gBRCA HER2-negative metastatic breast cancer.

Clinical trials showed that although Lynparza delays the time until cancer progresses compared to routine surveillance, it wasn’t cost-effective, the institute said.

“This is a disappointing decision for patients in the UK,” an AstraZeneca spokesperson said.

The company “will continue to engage with NICE, NHS England and the Cancer Drugs Fund with the aim of enabling access to this treatment for women with ovarian cancer.”